Osteal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel combination therapies for orthopedic infections, including periprosthetic joint infections (PJIs). The company’s lead product, VT-X7, is a drug/device combination that delivers therapeutic concentrations of vancomycin and tobramycin directly to the joint space, offering a rapid and effective alternative to current treatments, which are lengthy, invasive, and carry significant risks of morbidity and reduced quality of life.
Osteal completed an oversubscribed $23 million Series C financing, led by Asteroid Partners,{ an SPV formed by Marty and Steven } with participation from Johnson & Johnson Development Corporation, HM Capital, Prism Ventures, Medvest Capital, and Gideon Strategic Partners. Within the following year, the company completed a 50 million dollar series D. Osteal recently indicated that they are pending the completion of a series E round. The funding positions the company to submit its New Drug Application (NDA) to the FDA and advance toward commercial launch.
Martin Sands of Asteroid Partners highlighted the growing clinical need: “Hip and knee replacements are extremely common, and PJIs, while rare, closely track the number of these surgeries. The current standard of care carries high morbidity rates and reduced quality of life, driving the need for better treatment options. Osteal is addressing this significant unmet medical need with a highly novel approach.” His perspective underscores the potential of VT-X7 to transform outcomes for patients facing serious orthopedic infections.
JJDC, the Johnson and Johnson venture and development arm invested in the Series C round and both Zimmer Biomet and JJDC participated in the series D, which are viewed as strong endorsements. Osteals approach aims to address and /or eradicate biofilm-based infections efficiently while minimizing off-target effects, positioning VT-X7 as a first-of-its-kind solution in a multibillion-dollar opportunity space.
